DVA

DaVita Inc. 10-Q Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2005. DaVita Inc. is a leading provider of dialysis services in the United States. As of July 29, 2005, approximately 101.0 million shares of common stock were outstanding. The company is currently in the process of acquiring Gambro Healthcare, Inc., a major competitor, for approximately $3.05 billion, subject to regulatory approvals and divestitures.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenues increased 17.7% year-over-year for the quarter ended June 30, 2005, compared to June 30, 2004. This was driven by a 15% increase in dialysis treatments (5.5% organic growth, 9.5% from acquisitions) and higher ancillary revenues.
• Debt Restructuring: On March 22, 2005, the company issued $500 million of senior notes and $850 million of senior subordinated notes. Proceeds were used to repay all outstanding Term Loans. Consequently, debt expense increased significantly to $24.9 million for the quarter (up from $11.3 million in the prior year quarter) due to higher interest rates on the new fixed-rate debt.
• Acquisitions: In the first six months of 2005, the company acquired 31 dialysis centers for approximately $80.7 million. Additionally, the company is finalizing the acquisition of Gambro Healthcare, which includes a preliminary agreement to divest 70 centers to RenalAmerica for approximately $320 million to satisfy FTC requirements.
• One-Time Items: The company recorded a $2.1 million loss related to the ineffective portion of interest rate swaps and $6.9 million in refinancing charges during the period.

Guidance, Outlook, and Risks

• 2005 Outlook: Management projects operating income for 2005 to be 4% to 6% higher than 2004 levels, excluding the Gambro acquisition. The acquisition is expected to be dilutive to EPS in the first year, neutral in the second, and accretive thereafter. Integration costs are estimated at $50 million net of synergies in the first year.
• Capital Expenditures: The company expects to spend $100 million to $120 million on capital assets in 2005, split between routine maintenance and new center development.
• Legal and Regulatory Risks: The company is subject to multiple ongoing investigations by U.S. Attorneys' Offices (Missouri, New York, Pennsylvania) regarding billing practices, pharmaceutical services, and physician relationships. These investigations could result in substantial penalties or exclusion from government programs.
• Reimbursement Risks: Approximately 40% of revenues come from commercial payors and 50% from Medicare. The company faces risks from potential rate reductions, changes in Medicare ESRD reimbursement structures, and shifts in pharmaceutical practice patterns (e.g., Aranesp vs. EPO).

Investor Verification Checklist

• Gambro Acquisition Status: Verify the timeline for closing the $3.05 billion Gambro Healthcare acquisition and the completion of the 70-center divestiture to RenalAmerica.
• Debt Service Capacity: Assess the impact of the new fixed-rate debt (average effective rate 7.06%) on future cash flows and interest coverage ratios.
• Regulatory Investigations: Monitor developments in the three active U.S. Attorney investigations for potential fines, settlements, or operational restrictions.
• Commercial Payor Mix: Track the percentage of revenue from commercial payors versus Medicare, as a shift toward lower-paying government programs could compress margins.
• Pharmaceutical Costs: Review trends in EPO and vitamin D analog costs and utilization, which represent a significant portion of patient care costs and revenues.